Table 3.
Multivariate analysis for variables associated with pathologic complete response
| Variable | Multivariate analysis | |
|---|---|---|
| Odds ratio (95% CI) | p-value | |
| Sex (female vs. male) | 2.039 (1.053–3.950) | 0.035 |
| Chemotherapy regimen | ||
| Cisplatin/vinorelbine vs. cisplatin/taxane | 1.200 (0.706–2.038) | 0.071 |
| Cisplatin/vinorelbine vs. cisplatin/fluorouracil | 2.778 (1.160–6.657) | 0.022 |
| Post-CRT EGD finding (negative vs. positive) | 2.109 (1.243–3.579) | 0.006 |
| Pre-CRT NLR | 1.200 (1.025–1.406) | 0.024 |
| ALC nadir during CRT | 0.215 (0.070–0.666) | 0.008 |
| Post-CRT PLR | 1.004 (1.001–1.006) | 0.012 |
ALC, absolute lymphocyte count; CI, confidence interval; CRT, chemoradiotherapy; EGD, esophagogastroduodenoscopy; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio.